Colman et al v. Theranos, Inc. et al

  1. July 23, 2018

    Theranos Settles Indirect Investors' Fraud Suit

    Former high-flying Silicon Valley blood-testing company Theranos Inc., whose founder was indicted last month for criminal fraud, has settled a proposed class action brought by a group of indirect investors who claimed they were harmed by false and misleading statements made by the company, according to documents filed Friday in California federal court.

  2. June 26, 2018

    Theranos Founder's Stay Bid Nixed As Judge Scolds Counsel

    A California federal judge on Tuesday denied former Theranos Inc. CEO Elizabeth Holmes' request to stay a securities fraud suit brought by investors in the disgraced blood-testing startup she founded pending resolution of a newly filed criminal case, while also accusing her counsel of playing "litigation games" and hiding discovery.

  3. June 04, 2018

    Filmmaker Takes 2nd Crack At Theranos Deposition Footage

    A documentary filmmaker who is working on a project about scandal-ridden blood-testing company Theranos Inc. has asked a California federal judge to let him intervene in a securities suit and see deposition videos that Theranos seeks to keep confidential, telling the court Friday there is no good reason to block their release.

  4. June 01, 2018

    Theranos Indirect Investors Denied Class Cert. For Fraud Suit

    A California federal judge on Thursday refused to certify a group of indirect investors alleging securities fraud claims against the once high-flying blood testing company Theranos Inc., finding that weaknesses in the proposed class make individual actions preferable.

  5. September 06, 2017

    Theranos Gets Class Limited To Indirect Share Purchasers

    Theranos Inc. won a bid to exclude certain investors from a proposed class of stock buyers bringing securities fraud claims against the health care technology company, with a California federal court issuing an order Wednesday limiting the class to indirect purchasers of the shares.

  6. August 15, 2017

    Judge Rejects Theranos Investors' Bid To Pause Settlements

    A proposed class of Theranos Inc. investors is moving forward with a securities fraud suit against the health technology startup after losing a bid to pause the company's settlements with Walgreen Co. and others, deals the investors called a "preferential transfer of assets."

  7. July 03, 2017

    Theranos Wants Class Limited To Indirect Share Purchasers

    Theranos Inc. has urged a California federal court to exclude investors that directly bought shares from a proposed class of indirect share purchasers bringing securities fraud claims, saying only the former are bound by a contract.

  8. May 24, 2017

    Theranos Dodges Investors' 'Boundless' Docs Bid, For Now

    A California magistrate judge refused Wednesday to order Theranos to provide a putative shareholder class with all documents the beleaguered startup produced in similar, recently settled suits over claims it lied about the accuracy of its blood tests, saying he opened discovery, but "that doesn't mean discovery is boundless."

  9. May 04, 2017

    Theranos Shrugs Shoulders On Adding Funds To Investor Suit

    Blood testing venture Theranos Inc. told a California federal judge on Wednesday that it was indifferent to roping three investment funds into a potential shareholder class action against it, but reasserted that the plaintiffs have no right to sue after their case survived dismissal.

  10. April 27, 2017

    Investors Want Venture Funds Kept Out Of Theranos Suit

    Investors who purchased Theranos Inc. stocks through venture funds on Wednesday urged a California federal court not to rope the funds into the litigation, arguing there's no risk of double recovery and that the securities fraud lawsuit won't be hindered without their presence.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!